IV Ketamine Infusions for the Treatment of Depression: An Evidence Based Practice Analysis
Repository Posting Date2018-05-18T15:06:10Z
Author(s)Quinones, Sergio A.
TypeOther Graduate Paper
Level of EvidenceOther
Research ApproachPilot/Exploratory Study
CINAHL HeadingsAntidepressive Agents--Administration and Dosage; Depression--Drug Therapy; Ketamine--Administration and Dosage; Infusions, Intravenous; Antidepressive Agents; Depression--Prevention and Control; Depression; Ketamine
According to the World Health Organization, major depressive disorder (MDD) is a mental health condition which affects a significant portion of the worldwide population and is projected to become the leading cause of disability by 2020. There are several treatment options for the diagnosis of depression, with the most popular being antidepressant drugs such as the selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs); and electroconvulsive therapy (ECT). The significant drawbacks to the current treatments are the extended timeframe required for drugs to reach therapeutic efficacy and resistance to ECT over time. These disadvantages can lead to increased risk of self-harm and suicidal tendencies. A drug with fast onset and efficacy in treating depression can improve patient’s quality of life.